Quetiapine versus trazodone in reducing rehospitalization for alcohol dependence: A large data-base study

Journal of Addiction Medicine

Volumn 2, Issue 3, 2008, Pages 128-134

  Monnelly, Edward P ^a,d,e   Locastro, Joseph S ^a,c,d   Gagnon, David ^a,b,c   Young, Melissa ^a,b   Fiore, Louis D ^b,c  

^a Sections of Infectious Diseases and Cardiology   (United States)

^b Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC)   (United States)

^c BOSTON UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

Alcohol dependence; Quetiapine; Rehospitalization; Sleep disturbance; Trazodone

Indexed keywords

EID: 70349221257     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e318165cb56     Document Type: Article

References (39)

1. Anton RF, O'Malley SS, Ciraulo DA. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-2017.
2. Kranzler HR. Evidence-based treatments for alcohol dependence: new results and new questions. JAMA. 2006;295:2075-2076.
3. Caetano R, Clark CL, Greenfield TK. Prevalence, trends, and incidence of alcohol withdrawal symptoms: analysis of general population and clinical samples. Alcohol Health Res World. 1998;22:73-79.
4. National Institute on Alcohol Abuse and Alcoholism. Alcohol and Sleep. Alcohol Alert No. 41. 1998.
5. Satel SL, Kosten TR, Schuckit MA. Should protracted withdrawal from drugs be included in DSM-IV? Am J Psychiatry. 1993;150:695-704.
6. Aldrich M. Effects of alcohol on sleep. In: Gomberg ESL, Hegedus AM, Zucker RA, eds. Alcohol Problems and Aging: National Institute on Alcohol Abuse and Alcoholism Research Monograph 33. NIH Publication 98-4163. Bethesda: NIAAA; 1998:281-300.
7. Casola PG, Goldsmith RJ, Daiter J. Assessment and treatment of sleep problems. Psychiatr Ann. 2006;36:862-868.
8. Friedmann PD, Herman DS, Freedman S, et al. The treatment of sleep disturbance in alcohol recovery: a national survey of addiction medicine physicians. J Addict Dis. 2003;22:91-103.
9. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66:469-476.
10. Le Bon O, Murphy JR, Staner L. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. J Clin Psychopharmacol. 2003;23:377-383.
11. Friedmann PD, Rose JS, Swift RA, et al. Trazodone for sleep disturbance after detoxification from alcohol dependence: a double-blind, placebo-controlled trial. Paper presented at: 18th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry; November 29 -December 2, 2007; San Diego, CA.
12. Citrome L, Jaffe A, Levine J, et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv. 2004;55:1006-1013.
13. Zimmet SV, Strous Burgess RD. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol. 2000;20:94-98.
14. Monnelly EP, Ciraulo DA, Knapp C, et al. Quetiapine for the treatment of alcohol dependence. J Clin Psychopharmacol. 2004;24:532-535.
15. Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. Rev Psychiatr Neurosci. 2004;29:452-457.
16. Croissant BH, Diehl A, Severia L, et al. Quetiapine in alcohol relapse prevention: a case series. Alcohol Clin Exp Res. 2004;28(Suppl):p420.
17. Guardia J, Segura L, Gonzalvo B, et al. A double-blind, placebo controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol Clin Exp Res. 2004;28:736-745.
18. Kampman KM, Pettinatti HM, Lynch KG, et al. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol. 2007;27:344-351.
19. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Series B. 1972;34:187-220.
20. Binder DA. Fitting Cox's proportional hazards model from survey data. Biometrika. 1992;79:139-147.
21. Signorello LB, Mclaughlin JK, Lipworth L, et al. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Therapeut. 2002;9:199-205.
22. Longorio J, Brown ES, Perantie DC, et al. Quetiapine for alcohol use and craving in bipolar disorder. J Clin Psychopharmacol. 2004;24:101-102.
23. Lieberman JA. Comparative effectiveness of antipsychotic drugs. A commentary on cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). Arch Gen Psychiatry. 2006;63:1069-1072.
24. Jones PB, Barnes TRE, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079-1087.
25. Lieberman JA, Stroup S, McEvoy J, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005 22;353:1209-1223.
26. Ghaemi SN, Hsu DJ, Thase ME, et al. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatr Serv. 2006;57:660-665.
27. Besson J, Aeby R, Dsirge A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res. 1998;22:573-579.
28. Farren CK, O'Malley S. A pilot double blind placebo controlled trial of sertraline with naltrexone in the treatment of opiate dependence. Am J Addict. 2002;11:228-234.
29. Johnson BA, Swift RM, Ait-Daoud N, et al. Development of novel pharmacotherapies for the treatment of alcohol dependence: focus on antiepileptics. Alcohol Clin Exp Res. 2004;28:295-301.
30. Kiefer F, Jahn H, Tamaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92-99.
31. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291:1887-1996.
32. Mattson ME, Litten RZ. Combining treatments for alcoholism: why and how. J Stud Alcohol. 2005;(Suppl 15):8-16.
33. Meehl PE. Theoretical risks and tabular asterisks: Sir Karl, Sir Ronald, and the slow progress of soft psychology. J Cons Clin Psych. 1978;46:806-834.
34. Crum RM, Storr CL, Chan Y, et al. Sleep disturbance and risk for alcohol-related problems. Am J Psychiatry. 2004;161:1197-1203.
35. Butler DM. The demise of the blockbuster? N Engl J Med. 2007;356:1292-1293.
36. Johns LC, van Os J. The continuity of psychotic experiences in the general population. Clin Psychol Rev. 2001;21:1125-1141.
37. Kendler KS, Gallagher TJ, Abelson JM, et al. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry. 1996;53:1022-1031.
38. Roessler W, Riechler-Roessler A, Angst J, et al. Psychotic experiences in the general population: a twenty-year prospective community study. Schizophr Res. 2007;92:1-14.
39. Shevlin M, Murphy J, Dorahy MJ, et al. The distribution of positive psychosis-like symptoms in the population: a latent class analysis of the National Comorbidity Survey. Schizophr Res. 2007;89:101-109.